{"id":"NCT00368979","sponsor":"GlaxoSmithKline","briefTitle":"Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects","officialTitle":"Clinical Evaluation of Dutasteride in Benign Prostatic Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparative Study of GI198745 (Dutasteride) in Subjects With Benign Prostatic Hyperplasia.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02-17","primaryCompletion":"2007-12-01","completion":"2007-12-06","firstPosted":"2006-08-29","resultsPosted":"2009-04-02","lastUpdate":"2018-09-26"},"enrollment":378,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Prostatic Hyperplasia"],"interventions":[{"type":"DRUG","name":"Dutasteride","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dutasteride","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.","primaryOutcome":{"measure":"Change From Baseline in International Prostate Symptom Score (IPSS) at Week 52","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Placebo","deltaMin":-3.6,"sd":5.72},{"arm":"Dutasteride","deltaMin":-5.5,"sd":5.94}],"pValues":[{"comp":"OG000 vs OG001","p":"0.003"}]},"eligibility":{"minAge":"50 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":2},"locations":{"siteCount":26,"countries":["Japan"]},"refs":{"pmids":["19674165"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":184},"commonTop":["Nasopharyngitis","Diarrhoea","Upper respiratory tract inflammation","Back pain","Constipation"]}}